US20020130430A1 - Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products - Google Patents
Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products Download PDFInfo
- Publication number
- US20020130430A1 US20020130430A1 US09/750,473 US75047300A US2002130430A1 US 20020130430 A1 US20020130430 A1 US 20020130430A1 US 75047300 A US75047300 A US 75047300A US 2002130430 A1 US2002130430 A1 US 2002130430A1
- Authority
- US
- United States
- Prior art keywords
- fluid
- critical
- solution
- polymer
- spheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/12—Making granules characterised by structure or composition
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/12—Making granules characterised by structure or composition
- B29B2009/125—Micropellets, microgranules, microparticles
Definitions
- This invention relates to methods for making polymer microspheres and nanospheres and encapsulating therapeutic proteins and other products.
- the methods relate to improving the drug delivery of therapeutics and other products, and to making therapeutic proteins and other products more orally bioavailable.
- the methods feature supercritical, critical and near-critical fluids with and without polar cosolvents.
- aspects of the present invention employ materials known as supercritical, critical or near-critical fluids.
- a material becomes a critical fluid at conditions which equal its critical temperature and critical pressure.
- a material becomes a supercritical fluid at conditions which equal or exceed both its critical temperature and critical pressure.
- the parameters of critical temperature and critical pressure are intrinsic thermodynamic properties of all sufficiently stable pure compounds and mixtures.
- Carbon dioxide for example, becomes a supercritical fluid at conditions which equal or exceed its critical temperature of 31.1° C. and its critical pressure of 72.8 atm (1,070 psig).
- normally gaseous substances such as carbon dioxide become dense phase fluids which have been observed to exhibit greatly enhanced solvating power.
- carbon dioxide At a pressure of 3,000 psig (204 atm) and a temperature of 40° C., carbon dioxide has a density of approximately 0.8 g/cc and behaves much like a nonpolar organic solvent, having a dipole moment of zero debyes.
- a supercritical fluid displays a wide spectrum of solvation power as its density is strongly dependent upon temperature and pressure. Temperature changes of tens of degrees or pressure changes by tens of atmospheres can change a compound's solubility in a supercritical fluid by an order of magnitude or more. This feature allows for the fine-tuning of solvation power and the fractionation of mixed solutes.
- the selectivity of nonpolar supercritical fluid solvents can also be enhanced by addition of compounds known as modifiers (also referred to as entrainers or cosolvents). These modifiers are typically somewhat polar organic solvents such as acetone, ethanol, methanol, methylene chloride or ethyl acetate. Varying the proportion of modifier allows a wide latitude in the variation of solvent power.
- Embodiments of the present invention address these problems inherent in the prior art with the application of supercritical, critical or near-critical fluids.
- One embodiment of the present invention is a method of making polymeric spheres comprising the steps of providing a polymer solution of a polymeric material dissolved in a first fluid.
- the first fluid consisting of a supercritical, critical or near-critical fluid.
- the polymer solution is depressurized as said polymer solution exits one or more orifices in the presence of a low solubility fluid.
- the low solubility fluid has low volatility and the polymeric material is in a concentration which exceeds the solubility of the polymeric material in the low solubility fluid.
- the polymeric material forms spheres and the first fluid is removed during depressurization.
- Embodiments of the present invention feature the formation of spheres having an average diameter of between 0.01 and 10.0 microns and, most preferably, 0.1 and 1.0 microns.
- the narrow range of diameter of the microspheres that can be attained with the present method is unusual and surprising.
- Embodiments of the present method are used to incorporate bioactive materials in the spheres.
- the polymer solution has a bioactive material, wherein the bioactive material dissolved or held in said polymer solution as a suspension or emulsion.
- bioactive refers to compositions which cause a change or modification of a living organism in the nature of pharmaceuticals, drugs, toxins, biocides and the like.
- the bioactive material is dissolved in the first fluid or dissolved in, or is held as a suspension or as an emulsion in a further fluid and the further fluid is combined with the first fluid and polymeric material.
- the fluid used to dissolve or hold the bioactive material is a supercritical, critical or near-critical fluid.
- a preferred fluid is selected from the group of solvents consisting of PVA, PBS, and liquid nitrogen, with or without a cosolvent, such as an alcohol, an aqueous solvent such as distilled water or mixtures of the aforementioned.
- the polymer solution is depressurized to ambient pressure.
- a preferred polymer is selected from one or more of the group of polymers consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric nansanhydride) and poly(sebacic anhydride).
- Preferred first fluids comprise carbon dioxide, nitrous oxide, ethylene, ethane, propane and fluorohydrocarbons.
- the first fluid may also contain modifiers.
- Preferred modifiers are methanol, ethanol, propanol, butanol, methylene chloride, ethyl acetate and acetone.
- a preferred temperature and pressure for a SCCNC comprising carbon dioxide are a temperature in the range of 10 to 60° C. and a pressure in the range of 1,000 to 5,000 psig.
- One preferred method of making polymeric spheres having an average diameter of between 0.1 and 1.0 microns and a bioactive material comprises the steps of providing a polymer solution of a polymeric material in a first fluid, the first fluid consisting of a supercritical, critical or near-critical fluid. Next, the method comprises the step of providing a bioactive fluid having bioactive material. Next, an admixture of the first solution and the bioactive fluid is formed, to form a admixture solution, the admixture solution comprising a supercritical, critical or near-critical fluid. The admixture solution is depressurized as the admixture solution exits one or more orifices in the presence of a low solubility fluid.
- the low solubility fluid has low volatility and the polymeric material is in a concentration which exceeds its solubility in this fluid.
- the polymeric material forms spheres having an average diameter of 0.1 to 1.0 microns which spheres contain the bioactive material as the first fluid is removed during depressurization.
- the apparatus is used to make spheres having an average diameter of 0.01 to 10.0 microns and, most preferably, 0.1 to 1.0 microns.
- the admixture vessel receives a bioactive material.
- the bioactive material is dissolved in a solvent or held as a suspension in a fluid or held in an emulsion. Such bioactive material is incorporated into the spheres during depressurization.
- the apparatus further comprises a polymer vessel for forming a solution of a polymer in a supercritical, critical or near-critical fluid.
- the polymer vessel is in fluid communication with the admixture vessel.
- the apparatus further comprises a bioactive material vessel for forming a suspension, solution or emulsion of said bioactive material in a fluid.
- the bioactive vessel is in communication with the admixture vessel.
- SCCNC fluids also sterilize the materials in which such fluids are incorporated upon rapid depressurization, such as depressurization through an orifice.
- SCCNC fluids allow for easy removal of much of the solvent by mere depressurization. Use of a single apparatus to perform polymer sphere formation and encapsulate therapeutic proteins and other products minimizes labor and increases efficiency. Indeed, the entire process can be readily automated.
- the use of SCCNC fluids allows process conditions to be readily varied by temperature, pressure, or modifier solvents, minimizing equipment needs, processing time, potential for contamination, and loss of yield.
- the use of SCCNC fluids eliminates the need for toxic organic solvents such as in methylene chloride, ethyl acetate or DMSO and eliminates the presence of these toxic organic solvents in the final product.
- FIG. 1 depicts in schematic form an apparatus embodying features of the present invention
- FIG. 2 shows the in vitro time release characteristics of cytochrome-C from SCCNC polymer spheres
- FIG. 3 shows the in vitro time release characteristics of insulin from SCCNC polymer nanospheres.
- FIG. 1 depicts in schematic form a polymer sphere apparatus, generally designated by the numeral 11 .
- the polymer sphere apparatus is comprised of the following major elements: a polymer vessel 13 , a bioactive injection assembly 15 , an admixture chamber 17 , a depressurization vessel 19 , and an orifice nozzle 21 .
- Polymer vessel 13 is in fluid communication with a SCCNC syringe pump 25 via conduits 27 a and 27 b.
- SCNCC pump 25 is in fluid communication with a source of SCCNC fluid (not shown).
- Polymer vessel 13 is also in fluid communication with a modifier syringe pump 31 via conduit 33 which intersects with conduit 27 a and 27 b at junction 35 .
- Modifier syringe pump 31 is in communication with a source of modifiers and/or entrainers (not shown).
- Polymer vessel 13 is loaded with polymer. And, polymer vessel receives SCNCC fluid from SCNCC pump 25 via conduits 27 a and 27 b. Polymer vessel 13 receives modifiers and/or entrainers from Modifier pump 31 via conduit 33 . Polymer is dissolved in the SCNCC fluid and modifier to form a polymer solution.
- Admixture vessel 17 is in the nature of an inline mixer and thoroughly mixes incoming streams from the polymer vessel 13 and bioactive injection assembly 15 .
- Admixture vessel 17 is in communication with orifice nozzle 21 via conduit 49 .
- Orifice nozzle 21 is in the nature of a back pressure regulator and has a nozzle defining one or more orifices which discharge into depressurization vessel 19 via conduit 51 .
- Preferably orifice nozzle 21 controls pressure and decompression rates.
- the operating pressure of the system can be preset at a precise level via a computerized controller (not shown) that is part of the syringe pumps. Temperature control in the system is achieved by enclosing the apparatus 11 in 1 ⁇ 4′′ Lexan sheet while utilizing a Neslab heating/cooling system coupled with a heat exchanger (not shown) to maintain uniform temperature throughout the system.
- polymeric materials were first packed into the polymer vessel 13 .
- SCCNC and an ethanolic solution of insulin were charged into the SCNCC syringe pumps 25 and 31 , respectively, and brought to the desired operating pressure.
- a ethanol solution of insulin is charged into bioactive syringe pump 43 .
- the system was then pressurized with the SCCNC (supercritical fluid (SCF) and cosolvent) via SCNCC syringe pump 25 to the pressure level equal to that set in modifier syringe pump 31 and bioactive syringe pump 43 , and maintained at this level with the nozzle orifice 21 .
- the dynamic operating mode for all pumps were set so that each pump can be operated at its own desired flow rate.
- the SCCNC stream flowed through the polymer vessel 13 , dissolved polymer and contacted the insulin stream at junction 47 .
- the mixture of SCCNC, insulin and polymeric materials was then passed through admixture chamber 17 for further mixing.
- the mixed solution entered orifice nozzle 21 and was injected into a 0.1% PVA aqueous solution in the depressurization vessel 19 .
- polymeric spheres containing insulin are formed in the PVA aqueous solution and the expanded supercritical fluid exited the system via a vent line on the depressurization vessel 19 .
- Polymer microspheres/nanospheres were formed with 50:50 PLGA obtained from Sigma Chemicals (St. Louis, Mo.) in the SCCNC polymer sphere apparatus running in the continuous mode.
- the polymer microspheres/nanospheres were formed by injecting the SCCNC polymer solution into distilled water. The resulting product was observed under a light microscope, and the particle sizes were measured in a Coulter 4MD sub-micron particle size analyzer.
- the volume of distilled water used in PMF-03a was about half of that used in PMF-01 resulting in a more concentrated microsphere solution and a different particle size distribution.
- TT tetanus toxoid
- DT diphtheria toxoid
- DT diphtheria toxoid
- the pressure and temperature were around 3,000 psig and 30-35° C. respectively.
- the protein and antigenicity activities were performed by micro BCA assay and a sandwich-type capture ELISA [Gupta, R. K., Siber, G. R., Alonso, M. J.
- Toxoid SCCNC Protein (mg/ml) ELISA (Lf/ml) 1 Diphtheria Control 21.07 7.35 2 Diphtheria CO 2 /ethanol 1.49 0.13 3 Diphtheria C 3 H 8 18.63 6.55 4 Tetanus Control 30.44 9.0 5 Tetanus CO 2 /ethanol 9.81 0.44
- the data in Table 5 indicates that the Medisorb DL2M and DL2A bioadhesive polymers formed relatively uniform particle size distributions in the SCCNC CO 2 /ethanol and SCCNC CO 2 /acetone systems, respectively, at 3,000 psig and 50° C.
- the release characteristics of MS-25 were evaluated by suspending the dried microspheres in 4 ml of PBS at a pH of 7.4. Absorption of the solution was then measured at 408 nm and over the 350 to 450 nm range at different time intervals. Concentration was determined from a standard curve. The release characteristics of MS-25 over a 51 ⁇ 2 hour period is shown in FIG. 2.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention is for an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins and other useful substances. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize biodegradable polymers and form uniform polymer microspheres and nanospheres to encapsulate proteins with controlled-release characteristics.
Description
- This invention relates to methods for making polymer microspheres and nanospheres and encapsulating therapeutic proteins and other products. The methods relate to improving the drug delivery of therapeutics and other products, and to making therapeutic proteins and other products more orally bioavailable. The methods feature supercritical, critical and near-critical fluids with and without polar cosolvents.
- Aspects of the present invention employ materials known as supercritical, critical or near-critical fluids. A material becomes a critical fluid at conditions which equal its critical temperature and critical pressure. A material becomes a supercritical fluid at conditions which equal or exceed both its critical temperature and critical pressure. The parameters of critical temperature and critical pressure are intrinsic thermodynamic properties of all sufficiently stable pure compounds and mixtures. Carbon dioxide, for example, becomes a supercritical fluid at conditions which equal or exceed its critical temperature of 31.1° C. and its critical pressure of 72.8 atm (1,070 psig). In the supercritical fluid region, normally gaseous substances such as carbon dioxide become dense phase fluids which have been observed to exhibit greatly enhanced solvating power. At a pressure of 3,000 psig (204 atm) and a temperature of 40° C., carbon dioxide has a density of approximately 0.8 g/cc and behaves much like a nonpolar organic solvent, having a dipole moment of zero debyes.
- A supercritical fluid displays a wide spectrum of solvation power as its density is strongly dependent upon temperature and pressure. Temperature changes of tens of degrees or pressure changes by tens of atmospheres can change a compound's solubility in a supercritical fluid by an order of magnitude or more. This feature allows for the fine-tuning of solvation power and the fractionation of mixed solutes. The selectivity of nonpolar supercritical fluid solvents can also be enhanced by addition of compounds known as modifiers (also referred to as entrainers or cosolvents). These modifiers are typically somewhat polar organic solvents such as acetone, ethanol, methanol, methylene chloride or ethyl acetate. Varying the proportion of modifier allows a wide latitude in the variation of solvent power.
- In addition to their unique solubilization characteristics, supercritical fluids possess other physicochemical properties which add to their attractiveness as solvents. They can exhibit liquid-like density yet still retain gas-like properties of high diffusivity and low viscosity. The latter increases mass transfer rates, significantly reducing processing times. Additionally, the ultra-low surface tension of supercritical fluids allows facile penetration into microporous materials, increasing extraction efficiency and overall yields.
- A material at conditions that border its supercritical state will have properties that are similar to those of the substance in the supercritical state. These so-called “near-critical” fluids are also useful for the practice of this invention. For the purposes of this invention, a near-critical fluid is defined as a fluid which is (a) at a temperature between its critical temperature (Tc) and 75% of its critical temperature and at a pressure at least 75% of its critical pressure, or (b) at a pressure between its critical pressure (Pc) and 75% of its critical pressure and at a temperature at least 75% of its critical temperature. Inn this definition, pressure and temperature are defined on absolute scales, e.g., Kelvin and psia. Table 1 shows how these requirements relate to some of the fluids relevant to this invention. To simplify the terminology, materials which are utilized under conditions which are supercritical, near-critical, or exactly at their critical point will jointly be referred to as “SCCNC” fluids.
TABLE 1 Physical Properties of Critical Fluid Solvents Pvap BP (psia @ Tc Pc 0.75Tc 0.75Pc Fluid Formula (° C.) 25° C.) (° C.) (psia) (° C.) (psia) Carbon CO2 −78.5 860 31.1 1070 −45.0 803 dioxide Nitrous N2O −88.5 700 36.5 1051 −41.0 788 oxide Propane C3H8 −42.1 130 96.7 616 4.2 462 Ethane C2H6 −88.7 570 32.3 709 −44.1 531 Ethyl- C2H4 −103.8 NA 9.3 731 −61.4 548 ene Freon 11 CCl3F 23.8 15 198.1 639 80.3 480 Freon 21 CHCl2F 8.9 24 178.5 750 65.6 562 Freon 22 CHClF2 −40.8 140 96.1 722 3.8 541 Freon 23 CHF3 −82.2 630 26.1 700 −48.7 525 - Conventional methods of drug delivery such as tablets or injections provide an initial spike of therapeutic agent in the patient's system followed by a period of decay. Dosage is frequently limited by adverse side effects engendered by the elevated, albeit temporary, high level of agent. Furthermore, as the agent is cleared from the body, its concentration will most likely fall below a useful level prior to the next treatment. For many drugs, the ideal is a steady level over a prolonged period ranging from hours to years. This type of profile may be attained with the use of controlled release technology. Improved techniques for controlled release of therapeutic agents is an area of great importance to the medical field, the pharmaceutical industry, and the public that they serve.
- One of the most promising methods for controlled release involves the use of degradable or erodable polymers. These are typically formulated as microparticles or microspheres with a size ranging from a maximum of 50 μm down to approximately 0.1 μm. Following administration via ingestion or injection, the polymer is slowly eroded by body fluids to yield biocompatible breakdown products. Concurrently, drug is released from the particle by diffusion through the polymer matrix as well as by surface erosion.
- The most commonly used bioerodable polymers are of the poly(hydroxyacid) type, in particular poly(L-lactic acid), poly(D,L-lactic acid), poly(glycolic acid), and copolymers thereof. A typical copolymer used for microsphere/microparticle formation is poly(lactide-co-glycolide), abbreviated as PLGA. These materials are broken down in the body to the non-toxic products lactic acid and glycolic acid, and have been approved by the Food and Drug Administration for use as resorbable sutures, in bone implants, and as controlled release microspheres. Other polymers being utilized include poly(funimaric anhydride) and poly(sebacic anhydride). Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, M. and Morrell, C., Biologically Erodable Microspheres as Potential Oral Drug Delivery Systems,Nature, 386:410-414, 1997. The use of polymeric microspheres for controlled drug delivery has been the subject of a number of reviews. Langer, R., Cima, L. G., Tamada, J. A. and Wintermantel, E.: “Future Directions in Biomaterials,” Biomaterials, 11:738-745, 1990.
- At present, large scale production of polymeric microspheres utilize many processing steps and require large quantities of organic solvents. The process is very time consuming, costly and inefficient. Generally, such polymeric microspheres have a wide dispersion of particle size. Such polymeric spheres tend to have a median size greater than 100 microns in diameter. In addition, the exposure of therapeutic agent to the organic solvent may adversely affect the integrity of the final product. The process steps may also compromise sterility, or do not provide sterility.
- Embodiments of the present invention address these problems inherent in the prior art with the application of supercritical, critical or near-critical fluids.
- Embodiments of the present invention are directed to methods of using supercritical fluids for making uniform polymer spheres. The uniformity and integrity of such spheres make such spheres ideal for containing therapeutic proteins and other products. The methods require reduced processing time and preparation costs.
- One embodiment of the present invention is a method of making polymeric spheres comprising the steps of providing a polymer solution of a polymeric material dissolved in a first fluid. The first fluid consisting of a supercritical, critical or near-critical fluid. Next, the polymer solution is depressurized as said polymer solution exits one or more orifices in the presence of a low solubility fluid. The low solubility fluid has low volatility and the polymeric material is in a concentration which exceeds the solubility of the polymeric material in the low solubility fluid. The polymeric material forms spheres and the first fluid is removed during depressurization.
- Embodiments of the present invention feature the formation of spheres having an average diameter of between 0.01 and 10.0 microns and, most preferably, 0.1 and 1.0 microns. The narrow range of diameter of the microspheres that can be attained with the present method is unusual and surprising.
- Embodiments of the present method are used to incorporate bioactive materials in the spheres. Preferably, the polymer solution has a bioactive material, wherein the bioactive material dissolved or held in said polymer solution as a suspension or emulsion. As used herein, the term “bioactive” refers to compositions which cause a change or modification of a living organism in the nature of pharmaceuticals, drugs, toxins, biocides and the like.
- Preferably, the bioactive material is dissolved in the first fluid or dissolved in, or is held as a suspension or as an emulsion in a further fluid and the further fluid is combined with the first fluid and polymeric material. Preferably, the fluid used to dissolve or hold the bioactive material is a supercritical, critical or near-critical fluid. A preferred fluid is selected from the group of solvents consisting of PVA, PBS, and liquid nitrogen, with or without a cosolvent, such as an alcohol, an aqueous solvent such as distilled water or mixtures of the aforementioned.
- Preferably, the polymer solution is depressurized to ambient pressure. A preferred polymer is selected from one or more of the group of polymers consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric nansanhydride) and poly(sebacic anhydride). Preferred first fluids comprise carbon dioxide, nitrous oxide, ethylene, ethane, propane and fluorohydrocarbons. The first fluid may also contain modifiers. Preferred modifiers are methanol, ethanol, propanol, butanol, methylene chloride, ethyl acetate and acetone. A preferred temperature and pressure for a SCCNC comprising carbon dioxide are a temperature in the range of 10 to 60° C. and a pressure in the range of 1,000 to 5,000 psig.
- The low solubility fluid, preferably, comprises an aqueous solvent, such as distilled water; a cryogenic fluid, such as liquid nitrogen; an organic solvent, such as an alcohol; or a critical, supercritical or near-critical fluid or mixtures of the aforementioned. Preferably, the low solubility fluid has a chemical agent for stabilizing the polymeric spheres, by cross-linking or other means.
- One preferred method of making polymeric spheres having an average diameter of between 0.1 and 1.0 microns and a bioactive material comprises the steps of providing a polymer solution of a polymeric material in a first fluid, the first fluid consisting of a supercritical, critical or near-critical fluid. Next, the method comprises the step of providing a bioactive fluid having bioactive material. Next, an admixture of the first solution and the bioactive fluid is formed, to form a admixture solution, the admixture solution comprising a supercritical, critical or near-critical fluid. The admixture solution is depressurized as the admixture solution exits one or more orifices in the presence of a low solubility fluid. The low solubility fluid has low volatility and the polymeric material is in a concentration which exceeds its solubility in this fluid. The polymeric material forms spheres having an average diameter of 0.1 to 1.0 microns which spheres contain the bioactive material as the first fluid is removed during depressurization.
- A further embodiment of the present invention features an apparatus for forming one or more polymeric spheres. The apparatus comprises an admixture vessel, a depressurization chamber and an orifice. The admixture vessel is for receiving and containing a polymer solution of a polymeric material in a first fluid, the first fluid consisting of a supercritical, critical or near-critical fluid. The depressurization chamber contains a low solubility fluid and is in fluid communication with the admixture vessel by the orifice. The depressurization chamber receives the polymer solution as said polymer solution exits the orifices in the presence of a low solubility fluid. The low solubility fluid has low volatility and the polymeric material is in a concentration which exceeds its solubility in such fluid. The polymeric material forms spheres and the first fluid is removed during depressurization.
- The apparatus is used to make spheres having an average diameter of 0.01 to 10.0 microns and, most preferably, 0.1 to 1.0 microns.
- Preferably, the admixture vessel receives a bioactive material. The bioactive material is dissolved in a solvent or held as a suspension in a fluid or held in an emulsion. Such bioactive material is incorporated into the spheres during depressurization.
- Preferably, the apparatus further comprises a polymer vessel for forming a solution of a polymer in a supercritical, critical or near-critical fluid. The polymer vessel is in fluid communication with the admixture vessel.
- Preferably, the apparatus further comprises a bioactive material vessel for forming a suspension, solution or emulsion of said bioactive material in a fluid. The bioactive vessel is in communication with the admixture vessel.
- Sterile filtration and solvent evaporation can then be used to harvest the polymeric spheres. SCCNC fluids also sterilize the materials in which such fluids are incorporated upon rapid depressurization, such as depressurization through an orifice.
- Surprisingly and unexpectedly, uniform and stable polymeric spheres containing bioactive compositions, such as therapeutic proteins and drugs other products, are formed. The use of SCCNC fluids allows for easy removal of much of the solvent by mere depressurization. Use of a single apparatus to perform polymer sphere formation and encapsulate therapeutic proteins and other products minimizes labor and increases efficiency. Indeed, the entire process can be readily automated. The use of SCCNC fluids allows process conditions to be readily varied by temperature, pressure, or modifier solvents, minimizing equipment needs, processing time, potential for contamination, and loss of yield. The use of SCCNC fluids eliminates the need for toxic organic solvents such as in methylene chloride, ethyl acetate or DMSO and eliminates the presence of these toxic organic solvents in the final product.
- These and other features and advantages will be readily apparent from the drawing and detailed discussion which follow.
- FIG. 1 depicts in schematic form an apparatus embodying features of the present invention;
- FIG. 2 shows the in vitro time release characteristics of cytochrome-C from SCCNC polymer spheres; and,
- FIG. 3 shows the in vitro time release characteristics of insulin from SCCNC polymer nanospheres.
- The present method an apparatus will be described with respect to FIG. 1 which depicts in schematic form a polymer sphere apparatus, generally designated by the numeral11. The polymer sphere apparatus is comprised of the following major elements: a
polymer vessel 13, abioactive injection assembly 15, anadmixture chamber 17, adepressurization vessel 19, and anorifice nozzle 21. -
Polymer vessel 13 is in fluid communication with aSCCNC syringe pump 25 viaconduits SCNCC pump 25 is in fluid communication with a source of SCCNC fluid (not shown). -
Polymer vessel 13 is also in fluid communication with amodifier syringe pump 31 viaconduit 33 which intersects withconduit junction 35.Modifier syringe pump 31 is in communication with a source of modifiers and/or entrainers (not shown). -
Polymer vessel 13 is loaded with polymer. And, polymer vessel receives SCNCC fluid fromSCNCC pump 25 viaconduits Polymer vessel 13 receives modifiers and/or entrainers fromModifier pump 31 viaconduit 33. Polymer is dissolved in the SCNCC fluid and modifier to form a polymer solution. -
Polymer vessel 13 is in fluid communication withadmixture chamber 17 viaconduits 37 and 39.Admixture chamber 17 is also in fluid communication withbioactive injection assembly 15.Bioactive injection assembly 15 comprisesbioactive syringe pump 43, a source of bioactive material (not shown) andconduit 45.Bioactive syringe pump 43 is in communication with a source of bioactive material and pressurizes and compels such material throughconduit 45.Conduit 45 is in communication with admixture chamber via conduits 39 which intersectsconduit 45 atjunction 47. Preferablyjunction 47 is a mixing “T”. -
Admixture vessel 17 is in the nature of an inline mixer and thoroughly mixes incoming streams from thepolymer vessel 13 andbioactive injection assembly 15.Admixture vessel 17 is in communication withorifice nozzle 21 viaconduit 49.Orifice nozzle 21 is in the nature of a back pressure regulator and has a nozzle defining one or more orifices which discharge intodepressurization vessel 19 viaconduit 51. Preferablyorifice nozzle 21 controls pressure and decompression rates. - The operating pressure of the system can be preset at a precise level via a computerized controller (not shown) that is part of the syringe pumps. Temperature control in the system is achieved by enclosing the
apparatus 11 in ¼″ Lexan sheet while utilizing a Neslab heating/cooling system coupled with a heat exchanger (not shown) to maintain uniform temperature throughout the system. - In a typical experimental run, polymeric materials were first packed into the
polymer vessel 13. SCCNC and an ethanolic solution of insulin were charged into the SCNCC syringe pumps 25 and 31, respectively, and brought to the desired operating pressure. In the alternative, a ethanol solution of insulin is charged intobioactive syringe pump 43. - The system was then pressurized with the SCCNC (supercritical fluid (SCF) and cosolvent) via
SCNCC syringe pump 25 to the pressure level equal to that set inmodifier syringe pump 31 andbioactive syringe pump 43, and maintained at this level with thenozzle orifice 21. The dynamic operating mode for all pumps were set so that each pump can be operated at its own desired flow rate. The SCCNC stream flowed through thepolymer vessel 13, dissolved polymer and contacted the insulin stream atjunction 47. The mixture of SCCNC, insulin and polymeric materials was then passed throughadmixture chamber 17 for further mixing. Finally, the mixed solution enteredorifice nozzle 21 and was injected into a 0.1% PVA aqueous solution in thedepressurization vessel 19. As a result of supercritical fluid decompression, polymeric spheres containing insulin are formed in the PVA aqueous solution and the expanded supercritical fluid exited the system via a vent line on thedepressurization vessel 19. - For preliminary experiments, 50:50 mixtures of poly(D,L-lactic glycolic acid) with molecular weights of 3,000, 50,000 and 100,000 (Sigma Chemicals, St. Louis, Mo.) were utilized. For most microsphere and some solubility experiments, Medisorbn® biodegradable polymers (Alkermes, Inc., Cincinnati, Ohio) were utilized. The specifications on the Medisorb polymers are listed in Table 2. “A” indicates that the polymers contain a free carboxylic acid group on the carboxyl end of the polymer chain; “M” indicates an ester end group.
TABLE 2 Specifications of Medisorb ® Biodegradable Polymers Medisorb Inherent Viscosity Approx. MW DL-lactide/glycolide Polymer (dL/g) (Kd) mole ratio 5050DL2A 0.15 12.3 53/47 5050DL2M 0.18 17.3 54/46 5050DL3A 0.25-0.33 20-28 54/46 - Other materials utilized include insulin, cytochrome-C, tetanus and diphtheria toxoids, ethyl alcohol (USP grade), distilled water, and polyvinyl alcohol (PVA).
- Polymer microspheres/nanospheres were formed with 50:50 PLGA obtained from Sigma Chemicals (St. Louis, Mo.) in the SCCNC polymer sphere apparatus running in the continuous mode. The polymer microspheres/nanospheres were formed by injecting the SCCNC polymer solution into distilled water. The resulting product was observed under a light microscope, and the particle sizes were measured in a Coulter 4MD sub-micron particle size analyzer. The volume of distilled water used in PMF-03a was about half of that used in PMF-01 resulting in a more concentrated microsphere solution and a different particle size distribution. Some of these results are presented in Table 3.
TABLE 3 SCCNC Polymer Microspheres/Nanospheres Formed with 50:50 PLGA at 40° C. Pressure Flow Rate Small Medium Large Run No. SCCNC (psig) (ml/min) Size (nm)/% Size (nm)/% Size (nm)/% PMF-01 C3H8 2,000 1.0 99 (26%) 336 (74%) PMF-02a C3H8 4,000 1.0 120 (34%) 2,120 (66%) PMF-02b C3H8 5,000 3.0 33 (57%) 282 (15%) 10,000 (29%) PMF-03a C3H8 2,000 1.0 291 (76%) 1,770 (24%) PMF-03b C3H8 2,000 4.0 169 (33%) 852 (67%) - Experiments were performed to encapsulate tetanus toxoid (TT) and diphtheria toxoid (DT) vaccine antigens in 50:50 PLGA polymer microspheres formed by SCCNC carbon dioxide and propane. In these tests, DT and TT were each separately treated with supercritical carbon dioxide with 10% (v/v) cosolvent ethanol, and near-critical propane in the presence of PLGA. The pressure and temperature were around 3,000 psig and 30-35° C. respectively. The protein and antigenicity activities were performed by micro BCA assay and a sandwich-type capture ELISA [Gupta, R. K., Siber, G. R., Alonso, M. J. and Langer, R., inModern Approaches To New Vaccines Including Prevention of AIDS. Ed. by Ginsberg, H. S., Brown, F., Chanock, R. M. and Lerner, R. A. Cold Spring Harbor Laboratory, Press, 1993] assay. The results of this study are summarized in Table 4.
TABLE 4 Protein Content and Antigencity of Tetanus Toxoid and Diphtheria Toxoid in PLGA Polymer Microspheres formed by Different SCCNC Sample No. Toxoid SCCNC Protein (mg/ml) ELISA (Lf/ml) 1 Diphtheria Control 21.07 7.35 2 Diphtheria CO2/ethanol 1.49 0.13 3 Diphtheria C3H8 18.63 6.55 4 Tetanus Control 30.44 9.0 5 Tetanus CO2/ethanol 9.81 0.44 - Both diphtheria and tetanus toxoids lost most of their antigenicity after being treated with SCCNC carbon dioxide/ethanol mixtures. These losses are probably due to the fact that the acid/base equilibrium shifted due to the formation of carbonic acid when the aqueous protein is exposed to carbon dioxide. This shift can drastically reduce pH if the solution is insufficiently buffered. Both diphtheria and tetanus toxoids will denature at pH levels below 5.0. Thus, carbon dioxide may not be the best candidate for a SCCNC solvent for acid pH sensitive proteins. Propane, on the other hand, did little damage to the diphtheria toxoid because it has negligible impact on the acid/base equilibrium of the aqueous protein.
- Experiments were conducted to encapsulate insulin in polymer microspheres/nanospheres utilizing supercritical carbon dioxide. Insulin, which has an isoelectric point of 3.65, is stable at acid pHs. In these experiments, a feed solution of 0.1 mg/ml insulin in 90% ethanol:10% water was utilized. The supercritical carbon dioxide was pumped at a rate of 1 ml/min, the cosolvent pump at 0.1 ml/min, and the insulin solution at 0.5 ml/min. The resultant mixture was injected into 8 ml of 1% PVA solution for 30 minutes. The results of these experiments are summarized in Table 5.
TABLE 5 Polymer Microspheres/Nanospheres Formed with Medisorb Polymers and Insulin in SCCNC Carbon Dioxide/Cosolvent at 3,000 psig and 50° C. Small Medium Large Run No. Polymer SCCNC Size (nm) Size (nm) Size (nm)/% MS-09 DL2A CO2/ 750 (22%) 5,250 (77%) ethanol MS-10 DL2M CO2/ 634 (100%) ethanol MS-11 DL3A CO2/ 300 (49%) 10,000 (51%) ethanol MS-12 DL2A CO2/ 326 (100%) acetone - The data in Table 5 indicates that the Medisorb DL2M and DL2A bioadhesive polymers formed relatively uniform particle size distributions in the SCCNC CO2/ethanol and SCCNC CO2/acetone systems, respectively, at 3,000 psig and 50° C.
- In order to establish conditions for the encapsulation of proteins in uniform microspheres and their renlease characteristics, several experiments were conducted to encapsulate cytochrome-C in polymer microspheres/nanospheres utilizing supercritical carbon dioxide. In these experiments, a feed solution of 0.1 mg/ml cytochrome-C in 99% ethanol: 1% water was utilized. The supercritical carbon dioxide was pumped at a rate of 1.0 ml/min, the cosolvent pump at 0.1 ml/min, and the insulin solution at 0.5 ml/min. The resultant mixture was injected into 8 ml of 1% PVA solution for 30 minutes. The results of some of these experiments are summarized in Table 6.
TABLE 6 Polymer Microspheres/Nanospheres Formed with Medisorb Polymers and Cytochrome-C in SCCNC Carbon Dioxide and Propane at 3,000 psig Temp. Small Medium Large Run No. Polymer SCCNC (° C.) Size (nm) Size (nm) Size (nm) MS-19 DL3A CO2/10 % ethanol 45 318 (100%) MS-21 DL2A CO2/10 % ethanol 45 292 (100%) MS-22 DL2A CO2/10 % acetone 45 267 (100%) MS-23 DL2M CO2/10 % ethanol 45 239 (100%) MS-24 DL2A C3H8/10% acetone 30 187 (100%) MS-25 DL2A C3H8/3% acetone 40 418 (100%) - Some of the size distributions were quite narrow while others were broad. Some of the charts indicate the presence of “dust” which are particles that are larger than 10 micron in size. Most of these particles, from microscopic observations, appear to be excess polymer. These large polymer particles were removed by vacuum filtration prior to solvent evaporation and drying to harden the polymer microspheres/nanospheres. In experiments MS-24 and MS-25, the supercritical fluid and cosolvent pumps were kept in operation for 180 minutes after the feed pump was turned off to ensure that all the protein had been displaced from the high pressure circulation loop.
- The release characteristics of MS-25 were evaluated by suspending the dried microspheres in 4 ml of PBS at a pH of 7.4. Absorption of the solution was then measured at 408 nm and over the 350 to 450 nm range at different time intervals. Concentration was determined from a standard curve. The release characteristics of MS-25 over a 5½ hour period is shown in FIG. 2.
- In this example, a feed solution of 0.1 mg/ml insulin in 90% ethanol:10% water was utilized. Supercritical carbon dioxide was pumped at a rate of 1.0 ml/min, the cosolvent pump at 0.1 ml/min, and the insulin solution at 0.5 ml/min. The resultant mixture was injected into 8 ml of 1 % PVA solution for 30 minutes. The supercritical fluid and cosolvent pumps were kept in operation for 180 minutes after the feed pump was turned off to ensure that all the protein had been displaced from the high pressure circulation loop. The release characteristics of insulin in this experiment MS-27 was evaluated by suspending the dried microspheres in 4 ml of PBS at a pH of 7.4. Absorption of the solution was then measured at 280 nm and over the 250 to 350 nm range at different time intervals. The release characteristics of MS-27 over a 5-hour period are shown in FIG. 3.
- It is intended that the matter contained in the preceding description be interpreted in an illustrative rather than a limiting sense.
Claims (20)
1. A method of making polymeric spheres having an average diameter of between 0.01 and 10.0 microns, comprising the steps of:
a.) providing a polymer solution of a polymeric material dissolved in a first fluid, said first fluid consisting of a supercritical, critical or near-critical fluid; and,
b.) depressurizing said polymer solution as said polymer solution exits one or more orifices in the presence of a low solubility fluid, said low solubility fluid having low volatility and said polymeric material in a concentration which exceeds said solubility of said polymeric material in said low solubility fluid, said polymeric material forming spheres having an average diameter between 0.01 and 10.0 microns and said first fluid removed during depressurization.
2. The method of claim 1 wherein said spheres have an average diameter of between 0.1 to 1.0 microns.
3. The method of claim 1 wherein said polymer solution has a bioactive material, said bioactive material dissolved in said polymer solution or held in said polymer solution as a suspension or emulsion.
4. The method of claim 3 wherein said bioactive material is dissolved in said first fluid.
5. The method of claim 3 wherein said bioactive material is held as a suspension in said polymer solution.
6. The method of claim 3 wherein said bioactive material is held as an emulsion in said polymeric solution.
7. The method of claim 3 wherein said bioactive material is dissolved in a second fluid and said second is combined with said first fluid and polymeric material.
8. The method of claim 7 wherein said second fluid is a supercritical, critical or near-critical fluid.
9. The method of claim 7 wherein said bioactive material is held as a suspension in said second fluid.
10. The method of claim 3 wherein said bioactive material is held as an emulsion in said second fluid.
11. The method of claim 1 wherein said polymer solution is depressurized to ambient pressure.
12. The method of claim 1 wherein said low solubility fluid is selected from the group of solvents consisting of PVA, PBS, and liquid nitrogen.
13. The method of claim 1 wherein said polymer is selected from one or more of the group of polymers consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric anhydride) and poly(sebacic anhydride) and derivatives thereof.
14. A method of making polymeric spheres having an average diameter of between 0.01 and 10.0 microns, comprising the steps of:
a.) providing a polymer solution of a polymeric material in a first fluid, said first fluid consisting of a supercritical, critical or near-critical fluid;
b.) providing a second solution of a bioactive material in a second fluid;
c.) forming an admixture of said first solution and said second solution to form a third solution, said third solution comprising a supercritical, critical or near-critical fluid;
d.) depressurizing said third solution as said third solution exits one or more orifices in the presence of a low solubility fluid, said low solubility fluid having low volatility and said polymeric material in a concentration which exceeds said solubility of said polymeric material in said low solubility fluid, said polymeric material forming spheres having an average diameter of 0.01 to 10.0 microns, said spheres containing said bioactive material and said first fluid removed during depressurization.
15. The method of claim 14 wherein said spheres have an average diameter of between 0.1 to 1.0 microns.
16. An apparatus for forming one or more polymeric spheres having an average diameter of between 0.01 and 10.0 microns, comprising:
a.) an admixture vessel for receiving a polymer solution which polymer solution is a polymeric material dissolved in a first fluid, said first fluid consisting of a supercritical, critical or near-critical fluid;
b.) an orifice nozzle in communication with said admixture vessel for receiving said polymer solution; and,
c.) a depressurization vessel containing a low solubility fluid in communication with said orifice nozzle for receiving a stream of polymer solution as said polymer solution exits one or more orifices in the presence of said low solubility fluid, said low solubility fluid having low volatility and said polymeric material in a concentration which exceeds said solubility of said polymeric material in said low solubility fluid, said polymeric material forming spheres having an average diameter of 0.01 to 10.0 microns and said first fluid removed during depressurization.
17. The method of claim 16 wherein said spheres have an average diameter of between 0.1 to 1.0 microns.
18. The apparatus of claim 16 wherein said admixture vessel receives a bioactive material, said bioactive material dissolved in a solvent or held as a suspension in a fluid or held in an emulsion, and said bioactive material incorporated into said spheres during depressurization.
19. The apparatus of claim 16 wherein said apparatus further comprises a polymer vessel for forming a solution of a polymer in a supercritical, critical or near critical fluid, said polymer vessel in fluid communication with said admixture vessel.
20. The apparatus of claim 16 wherein said apparatus further comprises a bioactive material vessel for forming a suspension, solution or emulsion of said bioactive material in said polymer solution, said bioactive vessel in communication with said admixture vessel.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/750,473 US20020130430A1 (en) | 2000-12-29 | 2000-12-29 | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
US10/840,308 US7147806B2 (en) | 2000-12-29 | 2004-05-06 | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
US12/730,399 US8070467B2 (en) | 2000-12-29 | 2010-03-24 | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
US13/310,169 US8440614B2 (en) | 2000-12-29 | 2011-12-02 | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/750,473 US20020130430A1 (en) | 2000-12-29 | 2000-12-29 | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/840,308 Continuation US7147806B2 (en) | 2000-12-29 | 2004-05-06 | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020130430A1 true US20020130430A1 (en) | 2002-09-19 |
Family
ID=25017997
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/750,473 Abandoned US20020130430A1 (en) | 2000-12-29 | 2000-12-29 | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
US10/840,308 Expired - Lifetime US7147806B2 (en) | 2000-12-29 | 2004-05-06 | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/840,308 Expired - Lifetime US7147806B2 (en) | 2000-12-29 | 2004-05-06 | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
Country Status (1)
Country | Link |
---|---|
US (2) | US20020130430A1 (en) |
Cited By (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040192626A1 (en) * | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
US20040209831A1 (en) * | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
US20040231231A1 (en) * | 2002-12-20 | 2004-11-25 | Cataldo Dominic A. | Use of colloidal clays for sustained release of active ingredients |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US20050054598A1 (en) * | 2002-02-20 | 2005-03-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20050054596A1 (en) * | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050079610A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US20050084533A1 (en) * | 2002-03-13 | 2005-04-21 | Howdle Steven M. | Polymer composite with internally distributed deposition matter |
US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
US20050119212A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
US20050124567A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA) |
US20050124568A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
US20050136436A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA) |
US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US20050137153A1 (en) * | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20050153914A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA) |
US20050153915A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
US20050159376A1 (en) * | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050159382A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
US20050164968A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA) |
US20050164966A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050164967A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US20050164224A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US20050171039A1 (en) * | 2002-02-20 | 2005-08-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050176664A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA) |
US20050176666A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA) |
US20050182009A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA) |
US20050182006A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA) |
US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20050191638A1 (en) * | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
US20050196765A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20050203040A1 (en) * | 2001-05-18 | 2005-09-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US20050209180A1 (en) * | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20050222064A1 (en) * | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
US20050222066A1 (en) * | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US20050233329A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
US20050233997A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US20050233996A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20050233344A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
US20050256068A1 (en) * | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
US20050267058A1 (en) * | 2001-05-18 | 2005-12-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA) |
US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050287128A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
US20060019913A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US20060142226A1 (en) * | 2001-05-18 | 2006-06-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) |
US20060211642A1 (en) * | 2001-05-18 | 2006-09-21 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
US20060217332A1 (en) * | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20060241075A1 (en) * | 2001-05-18 | 2006-10-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA) |
US20070102836A1 (en) * | 2004-01-28 | 2007-05-10 | Japan Science And Technology Agency | Method for producing fine particles using method of rapid expansion into poor solvent from supercritical fluid |
US20070160980A1 (en) * | 2001-05-18 | 2007-07-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20070203333A1 (en) * | 2001-11-30 | 2007-08-30 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20070270579A1 (en) * | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20070276134A1 (en) * | 2006-05-24 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and organic cations |
US20070275923A1 (en) * | 2006-05-25 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY |
US20070281900A1 (en) * | 2006-05-05 | 2007-12-06 | Nastech Pharmaceutical Company Inc. | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY |
US20070293657A1 (en) * | 2006-02-17 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Complexes and methods of forming complexes of ribonucleic acids and peptides |
US20080039414A1 (en) * | 2002-02-20 | 2008-02-14 | Sima Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20080131431A1 (en) * | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
US20080261304A1 (en) * | 2004-04-20 | 2008-10-23 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
US20080274275A1 (en) * | 2004-11-29 | 2008-11-06 | Japan Science And Technology Agency | Method For Preparing Composite Fine Particles |
WO2008137758A2 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
US20090042298A1 (en) * | 2004-05-04 | 2009-02-12 | Mdrna, Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
WO2009055487A1 (en) | 2007-10-22 | 2009-04-30 | The Regents Of The University Of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
US20090137500A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
WO2009140679A2 (en) | 2008-05-16 | 2009-11-19 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20100239579A1 (en) * | 2006-05-15 | 2010-09-23 | Viral Logic Systems Technology Corp. | CD47 Related Compositions and Methods for Treating Immunological Diseases and Disorders |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20110172141A1 (en) * | 2008-07-11 | 2011-07-14 | Critical Pharmaceuticals Limited | Process for preparing microparticles |
US20110178157A1 (en) * | 2009-12-09 | 2011-07-21 | Nitto Denko Technical Corporation | Modulation of hsp47 expression |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
WO2011163436A1 (en) | 2010-06-24 | 2011-12-29 | Quark Pharmaceuticals, Inc. | Double stranded rna compounds to rhoa and use thereof |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012044979A2 (en) | 2010-10-01 | 2012-04-05 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Manipulation of stem cell function by p53 isoforms |
WO2012047631A2 (en) | 2010-09-27 | 2012-04-12 | The Children's Hospital Of Philadelphia | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
WO2012112691A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
WO2012118910A2 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP2518509A2 (en) | 2008-03-05 | 2012-10-31 | The Regents of the University of California | Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP. |
EP2522754A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
WO2012101639A3 (en) * | 2011-01-24 | 2012-12-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles based for dermal and systemic delivery of drugs |
WO2013010998A2 (en) | 2011-07-15 | 2013-01-24 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compositions and methods for immunomodulation |
EP2589961A2 (en) | 2006-09-06 | 2013-05-08 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
WO2013090648A1 (en) * | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013106494A1 (en) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
EP2617434A1 (en) | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
WO2014043292A1 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
WO2014043289A2 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2014138687A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Peptides and compositions for treatment of joint damage |
WO2015020960A1 (en) | 2013-08-09 | 2015-02-12 | Novartis Ag | Novel lncrna polynucleotides |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
EP2902013A1 (en) | 2008-10-16 | 2015-08-05 | Marina Biotech, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
WO2015123496A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2015175487A1 (en) | 2014-05-13 | 2015-11-19 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
WO2016011083A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP3054968A1 (en) * | 2013-10-08 | 2016-08-17 | Ferring BV | Microparticles comprising gnrh made by pgss |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2016176745A1 (en) | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
US9994915B2 (en) | 2010-10-11 | 2018-06-12 | Sanford-Burnham Medical Research Institute | miR-211 expression and related pathways in human melanoma |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20180161404A1 (en) * | 2015-06-09 | 2018-06-14 | B. G. Negev Technologies And Applications Ltd | Controlled release system for pulmonary delivery of surfactant protein d |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
EP3495488A1 (en) | 2008-10-27 | 2019-06-12 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
US10858647B2 (en) | 2013-03-15 | 2020-12-08 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
EP3808763A1 (en) | 2019-10-17 | 2021-04-21 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for immunomodulation |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
US11110500B2 (en) * | 2016-11-28 | 2021-09-07 | Tzu-Chi LIN | Uniform temperature roller system having uniform heat exchange by supercritical fluid |
US11234994B2 (en) | 2016-04-14 | 2022-02-01 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024126765A1 (en) | 2022-12-16 | 2024-06-20 | Université De Strasbourg | Rnai-based therapies targeting claudin-1 for the treatment and prevention of fibrotic diseases |
EP4410825A1 (en) | 2023-02-03 | 2024-08-07 | Servizo Galego de Saude | Fragments of the n-terminal domain of gsdmb for the treatment of cancer |
WO2024163747A2 (en) | 2023-02-02 | 2024-08-08 | University Of Rochester | Competitive replacement of glial cells |
US12089928B2 (en) | 2017-05-18 | 2024-09-17 | Wear2B Ltd. | Device, system and method for non-invasive monitoring of physiological measurements |
US12109274B2 (en) | 2015-09-17 | 2024-10-08 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
US20060078573A1 (en) * | 2004-06-11 | 2006-04-13 | Theodore Randolph | Methods of modifying crystal habit |
WO2008117313A1 (en) * | 2007-03-28 | 2008-10-02 | National Institute Of Immunology | Polymer particles based vaccine |
GB0810990D0 (en) * | 2008-06-16 | 2008-07-23 | Q Chip Ltd | Device and method of making solid beads |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
WO2012103182A1 (en) | 2011-01-28 | 2012-08-02 | Cerulean Pharma Inc. | Method for fabricating nanoparticles |
US20130122106A1 (en) * | 2011-10-19 | 2013-05-16 | Aphios Corporation | Dosage form, and methods of making and using the same, to produce immunization in animals and humans |
PT108368B (en) * | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Continuous production of particles |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582731A (en) * | 1983-09-01 | 1986-04-15 | Battelle Memorial Institute | Supercritical fluid molecular spray film deposition and powder formation |
US4734451A (en) * | 1983-09-01 | 1988-03-29 | Battelle Memorial Institute | Supercritical fluid molecular spray thin films and fine powders |
US5043280A (en) * | 1987-12-28 | 1991-08-27 | Schwarz Pharma Ag | Method and apparatus for the manufacture of a product having a substance embedded in a carrier |
US5554382A (en) * | 1993-05-28 | 1996-09-10 | Aphios Corporation | Methods and apparatus for making liposomes |
US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
US6124226A (en) * | 1994-11-14 | 2000-09-26 | Union Carbide Chemicals & Plastics Technology Corporation | Process for forming a catalyst, catalyst support or catalyst precursor with compressed fluids |
-
2000
- 2000-12-29 US US09/750,473 patent/US20020130430A1/en not_active Abandoned
-
2004
- 2004-05-06 US US10/840,308 patent/US7147806B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582731A (en) * | 1983-09-01 | 1986-04-15 | Battelle Memorial Institute | Supercritical fluid molecular spray film deposition and powder formation |
US4734451A (en) * | 1983-09-01 | 1988-03-29 | Battelle Memorial Institute | Supercritical fluid molecular spray thin films and fine powders |
US5043280A (en) * | 1987-12-28 | 1991-08-27 | Schwarz Pharma Ag | Method and apparatus for the manufacture of a product having a substance embedded in a carrier |
US5554382A (en) * | 1993-05-28 | 1996-09-10 | Aphios Corporation | Methods and apparatus for making liposomes |
US6124226A (en) * | 1994-11-14 | 2000-09-26 | Union Carbide Chemicals & Plastics Technology Corporation | Process for forming a catalyst, catalyst support or catalyst precursor with compressed fluids |
US5766637A (en) * | 1996-10-08 | 1998-06-16 | University Of Delaware | Microencapsulation process using supercritical fluids |
Cited By (277)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20050164224A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
US20050079610A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US20070270579A1 (en) * | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
US20050119212A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
US20050176664A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA) |
US20050124567A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA) |
US20050124568A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
US20050124566A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
US20050136436A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA) |
US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US20070160980A1 (en) * | 2001-05-18 | 2007-07-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20050153914A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA) |
US20050153915A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
US20060241075A1 (en) * | 2001-05-18 | 2006-10-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA) |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050159382A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
US20050164968A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA) |
US20050164966A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20060217332A1 (en) * | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20060019913A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US20050164967A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050267058A1 (en) * | 2001-05-18 | 2005-12-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA) |
US20050182009A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA) |
US20050182006A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA) |
US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20060216747A1 (en) * | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
US20050196765A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20050203040A1 (en) * | 2001-05-18 | 2005-09-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US20050209180A1 (en) * | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20060211642A1 (en) * | 2001-05-18 | 2006-09-21 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
US20050222066A1 (en) * | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US20060142226A1 (en) * | 2001-05-18 | 2006-06-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) |
US20050233997A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US20060025361A1 (en) * | 2001-05-18 | 2006-02-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US20050233344A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
US20050256068A1 (en) * | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
US20050176666A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA) |
US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050287128A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
US20050054596A1 (en) * | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20070203333A1 (en) * | 2001-11-30 | 2007-08-30 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US9738899B2 (en) | 2002-02-20 | 2017-08-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050054598A1 (en) * | 2002-02-20 | 2005-03-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20050233329A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
US20050222064A1 (en) * | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
US20050191638A1 (en) * | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20060217334A1 (en) * | 2002-02-20 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060217337A1 (en) * | 2002-02-20 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060217336A1 (en) * | 2002-02-20 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060217335A1 (en) * | 2002-02-20 | 2006-09-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050171039A1 (en) * | 2002-02-20 | 2005-08-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050159376A1 (en) * | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
US20060247428A1 (en) * | 2002-02-20 | 2006-11-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060275903A1 (en) * | 2002-02-20 | 2006-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060281175A1 (en) * | 2002-02-20 | 2006-12-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060287266A1 (en) * | 2002-02-20 | 2006-12-21 | Sirna Therapeutics, Inc. | RNA interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060293272A1 (en) * | 2002-02-20 | 2006-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20060292691A1 (en) * | 2002-02-20 | 2006-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20070004667A1 (en) * | 2002-02-20 | 2007-01-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7176304B2 (en) | 2002-02-20 | 2007-02-13 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US10889815B2 (en) | 2002-02-20 | 2021-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050137153A1 (en) * | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
US20070167393A1 (en) * | 2002-02-20 | 2007-07-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US10662428B2 (en) | 2002-02-20 | 2020-05-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
US7989612B2 (en) | 2002-02-20 | 2011-08-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10351852B2 (en) | 2002-02-20 | 2019-07-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20080039414A1 (en) * | 2002-02-20 | 2008-02-14 | Sima Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10000754B2 (en) | 2002-02-20 | 2018-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20040209831A1 (en) * | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
US20050233996A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9957517B2 (en) | 2002-02-20 | 2018-05-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8846894B2 (en) | 2002-02-20 | 2014-09-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9732344B2 (en) | 2002-02-20 | 2017-08-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20090137500A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9771588B2 (en) | 2002-02-20 | 2017-09-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040192626A1 (en) * | 2002-02-20 | 2004-09-30 | Mcswiggen James | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050084533A1 (en) * | 2002-03-13 | 2005-04-21 | Howdle Steven M. | Polymer composite with internally distributed deposition matter |
US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20040231231A1 (en) * | 2002-12-20 | 2004-11-25 | Cataldo Dominic A. | Use of colloidal clays for sustained release of active ingredients |
US20070102836A1 (en) * | 2004-01-28 | 2007-05-10 | Japan Science And Technology Agency | Method for producing fine particles using method of rapid expansion into poor solvent from supercritical fluid |
US20080261304A1 (en) * | 2004-04-20 | 2008-10-23 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
US20090042298A1 (en) * | 2004-05-04 | 2009-02-12 | Mdrna, Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
US8299236B2 (en) | 2004-05-04 | 2012-10-30 | Marina Biotech, Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20080274275A1 (en) * | 2004-11-29 | 2008-11-06 | Japan Science And Technology Agency | Method For Preparing Composite Fine Particles |
US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
US20070293657A1 (en) * | 2006-02-17 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Complexes and methods of forming complexes of ribonucleic acids and peptides |
US20070281900A1 (en) * | 2006-05-05 | 2007-12-06 | Nastech Pharmaceutical Company Inc. | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
US20080131431A1 (en) * | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
US20100239579A1 (en) * | 2006-05-15 | 2010-09-23 | Viral Logic Systems Technology Corp. | CD47 Related Compositions and Methods for Treating Immunological Diseases and Disorders |
US20070276134A1 (en) * | 2006-05-24 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and organic cations |
US20070275923A1 (en) * | 2006-05-25 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY |
EP2679998A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2679999A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2589961A2 (en) | 2006-09-06 | 2013-05-08 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
EP2680000A1 (en) | 2006-09-06 | 2014-01-01 | The Regents of the University of California | Molecular diagnosis and classification of malignant melanoma |
WO2008137758A2 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
EP2494993A2 (en) | 2007-05-04 | 2012-09-05 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
EP3434259A1 (en) | 2007-05-04 | 2019-01-30 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
EP2522754A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2522752A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2522753A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2522755A1 (en) | 2007-08-13 | 2012-11-14 | Baxter International Inc | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
EP2924435A2 (en) | 2007-10-22 | 2015-09-30 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
WO2009055487A1 (en) | 2007-10-22 | 2009-04-30 | The Regents Of The University Of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
EP2518509A2 (en) | 2008-03-05 | 2012-10-31 | The Regents of the University of California | Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP. |
WO2009140679A2 (en) | 2008-05-16 | 2009-11-19 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes |
US9226900B2 (en) | 2008-07-11 | 2016-01-05 | Critical Pharmaceuticals Limited | Process for preparing microparticles |
US20110172141A1 (en) * | 2008-07-11 | 2011-07-14 | Critical Pharmaceuticals Limited | Process for preparing microparticles |
EP2902013A1 (en) | 2008-10-16 | 2015-08-05 | Marina Biotech, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
EP3495488A1 (en) | 2008-10-27 | 2019-06-12 | Baxalta GmbH | Models of thrombotic thrombocytopenic purpura and methods of use thereof |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US9206424B2 (en) | 2009-12-09 | 2015-12-08 | Nitto Denko Corporation | Modulation of HSP47 expression |
US10093923B2 (en) | 2009-12-09 | 2018-10-09 | Nitto Denko Corporation | Modulation of HSP47 expression |
EP3012324A2 (en) | 2009-12-09 | 2016-04-27 | Nitto Denko Corporation | Modulation of hsp47 expression |
US8710209B2 (en) | 2009-12-09 | 2014-04-29 | Nitto Denko Corporation | Modulation of HSP47 expression |
EP3434773A2 (en) | 2009-12-09 | 2019-01-30 | Nitto Denko Corporation | Modulation of hsp47 expression |
US20110178157A1 (en) * | 2009-12-09 | 2011-07-21 | Nitto Denko Technical Corporation | Modulation of hsp47 expression |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
WO2011163436A1 (en) | 2010-06-24 | 2011-12-29 | Quark Pharmaceuticals, Inc. | Double stranded rna compounds to rhoa and use thereof |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP4079856A1 (en) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP3372684A1 (en) | 2010-08-24 | 2018-09-12 | Sirna Therapeutics, Inc. | Single-stranded rnai agents containing an internal, non-nucleic acid spacer |
WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012047631A2 (en) | 2010-09-27 | 2012-04-12 | The Children's Hospital Of Philadelphia | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2012044979A2 (en) | 2010-10-01 | 2012-04-05 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Manipulation of stem cell function by p53 isoforms |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9701965B2 (en) | 2010-10-01 | 2017-07-11 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9994915B2 (en) | 2010-10-11 | 2018-06-12 | Sanford-Burnham Medical Research Institute | miR-211 expression and related pathways in human melanoma |
US9970005B2 (en) | 2010-10-29 | 2018-05-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
EP3327125A1 (en) | 2010-10-29 | 2018-05-30 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
US11932854B2 (en) | 2010-10-29 | 2024-03-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11193126B2 (en) | 2010-10-29 | 2021-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
WO2012101639A3 (en) * | 2011-01-24 | 2012-12-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles based for dermal and systemic delivery of drugs |
WO2012112691A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
WO2012118910A2 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
US10898574B2 (en) | 2011-03-31 | 2021-01-26 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US11911474B2 (en) | 2011-03-31 | 2024-02-27 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
US9044420B2 (en) | 2011-04-08 | 2015-06-02 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
WO2013010998A2 (en) | 2011-07-15 | 2013-01-24 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compositions and methods for immunomodulation |
EP2557089A2 (en) | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
EP3048111A1 (en) | 2011-07-15 | 2016-07-27 | Fundació Institut de Recerca Biomèdica de Bellvitge | Compositions and methods for immunomodulation |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
US8754062B2 (en) | 2011-12-16 | 2014-06-17 | Moderna Therapeutics, Inc. | DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides |
US8680069B2 (en) | 2011-12-16 | 2014-03-25 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of G-CSF |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US8664194B2 (en) | 2011-12-16 | 2014-03-04 | Moderna Therapeutics, Inc. | Method for producing a protein of interest in a primate |
WO2013090648A1 (en) * | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
CN104114572A (en) * | 2011-12-16 | 2014-10-22 | 现代治疗公司 | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
WO2013106494A1 (en) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
EP2617434A1 (en) | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9782462B2 (en) | 2012-04-02 | 2017-10-10 | Modernatx, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
WO2014043292A1 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to p53 and methods of use thereof |
WO2014043289A2 (en) | 2012-09-12 | 2014-03-20 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
EP3391900A1 (en) | 2013-03-08 | 2018-10-24 | Novartis AG | Peptides and compositions for treatment of joint damage |
WO2014138687A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Peptides and compositions for treatment of joint damage |
US10858647B2 (en) | 2013-03-15 | 2020-12-08 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US11845772B2 (en) | 2013-03-15 | 2023-12-19 | Modernatx, Inc. | Ribonucleic acid purification |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
WO2015020960A1 (en) | 2013-08-09 | 2015-02-12 | Novartis Ag | Novel lncrna polynucleotides |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3054968A1 (en) * | 2013-10-08 | 2016-08-17 | Ferring BV | Microparticles comprising gnrh made by pgss |
US10441626B2 (en) | 2013-10-08 | 2019-10-15 | Ferring Bv | Microparticles comprising GNRH made by PGSS |
JP2016534040A (en) * | 2013-10-08 | 2016-11-04 | フェリング ベスローテン フェンノートシャップ | Fine particles containing GNRH produced by PGSS |
WO2015123496A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
WO2015175487A1 (en) | 2014-05-13 | 2015-11-19 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
WO2016011083A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
WO2016176745A1 (en) | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
US10682396B2 (en) * | 2015-06-09 | 2020-06-16 | B.G. Negev Technologies And Applications Ltd | Controlled release system for pulmonary delivery of surfactant protein D |
US20180161404A1 (en) * | 2015-06-09 | 2018-06-14 | B. G. Negev Technologies And Applications Ltd | Controlled release system for pulmonary delivery of surfactant protein d |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US12109274B2 (en) | 2015-09-17 | 2024-10-08 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
US12071620B2 (en) | 2015-09-17 | 2024-08-27 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US11234994B2 (en) | 2016-04-14 | 2022-02-01 | Benitec Biopharma Limited | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
WO2018011433A1 (en) | 2016-07-15 | 2018-01-18 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Methods and compositions for the treatment of cancer |
EP3269734A1 (en) | 2016-07-15 | 2018-01-17 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods and compositions for the treatment of cancer |
US11427621B2 (en) | 2016-07-15 | 2022-08-30 | Institucio Catalana De Recerca I Estudis Avancats | Methods and compositions for the treatment of cancer |
US11110500B2 (en) * | 2016-11-28 | 2021-09-07 | Tzu-Chi LIN | Uniform temperature roller system having uniform heat exchange by supercritical fluid |
US12089928B2 (en) | 2017-05-18 | 2024-09-17 | Wear2B Ltd. | Device, system and method for non-invasive monitoring of physiological measurements |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
EP3808763A1 (en) | 2019-10-17 | 2021-04-21 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for immunomodulation |
WO2021074449A1 (en) | 2019-10-17 | 2021-04-22 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Compounds for immunomodulation |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
WO2023069987A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Rejuvenation treatment of age-related white matter loss cross reference to related application |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024126765A1 (en) | 2022-12-16 | 2024-06-20 | Université De Strasbourg | Rnai-based therapies targeting claudin-1 for the treatment and prevention of fibrotic diseases |
WO2024163747A2 (en) | 2023-02-02 | 2024-08-08 | University Of Rochester | Competitive replacement of glial cells |
WO2024161037A1 (en) | 2023-02-03 | 2024-08-08 | Servizo Galego De Saúde | Fragments of the n-terminal domain of gsdmb for the treatment of cancer. |
EP4410825A1 (en) | 2023-02-03 | 2024-08-07 | Servizo Galego de Saude | Fragments of the n-terminal domain of gsdmb for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
US7147806B2 (en) | 2006-12-12 |
US20060033224A1 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020130430A1 (en) | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products | |
US8070467B2 (en) | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein | |
Cui et al. | Preparation and characterization of melittin-loaded poly (DL-lactic acid) or poly (DL-lactic-co-glycolic acid) microspheres made by the double emulsion method | |
Das et al. | Solid dispersions: an approach to enhance the bioavailability of poorly water-soluble drugs | |
Berkland et al. | Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres | |
Cleek et al. | Microparticles of poly (DL-lactic-co-glycolic acid)/poly (ethylene glycol) blends for controlled drug delivery | |
US6534094B2 (en) | Manufacturing process of microcapsules for sustained release of water soluble peptides | |
Wang et al. | The application of a supercritical antisolvent process for sustained drug delivery | |
US5424076A (en) | Method of producing microscopic particles made of hydrolytically decomposable polymers and containing active substances | |
Kim et al. | Characteristics of felodipine-located poly (ε-caprolactone) microspheres | |
EP2595606A2 (en) | Method for preparing microspheres and microspheres produced thereby | |
US7691412B2 (en) | Prolonged release biodegradable microspheres and method for preparing same | |
NL9320034A (en) | Salts of peptides with carboxy-terminated polyesters. | |
CN109414401B (en) | Biodegradable polymeric microsphere compositions for parenteral administration | |
Bain et al. | Solvent influence on spray-dried biodegradable microspheres | |
WO2018137629A1 (en) | Risperidone sustained release composition and preparation method therefor | |
US9539213B2 (en) | Method of preparing microspheres by using polymer having sol-gel transition property and microspheres prepared thereby | |
Pawar et al. | Long-acting microspheres of Human Chorionic Gonadotropin hormone: In-vitro and in-vivo evaluation | |
JP2867404B2 (en) | Porous microspheres for drug delivery and method for producing the same | |
Iwata et al. | Selection of the solvent system for the preparation of poly (D, L-lactic-co-glycolic acid) microspheres containing tumor necrosis factor-alpha (TNF-α) | |
KR102427305B1 (en) | A manufacturing method of double encapsulated biodegradable polymer microsphere, and the injection composition containing the same | |
CN114767638A (en) | Preparation method of ibuprofen-loaded polylactic acid degradable microspheres | |
WO2023015851A1 (en) | Triamcinolone acetonide microsphere implant used for injection and preparation method therefor | |
Huang | Fabrication of porous poly (?-caprolactone) microparticles for protein release | |
Hincal et al. | Microsphere preparation by solvent evaporation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |